Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Tofacitinib

Status:

Phase 1

Condition:

Sarcoidosis ILD

Intervention Type:

Oral Drug

Funder Type:

Organization | University

Drug Details

Tofacitinib (XELJANZ®) is an oral, small molecule drug called a Janus kinase (JAK) inhibitor.

Study Purpose

This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary endpoint for this study is a 50% or greater reduction in corticosteroid requirement.

Find a Clinical Trial